CABA News and Press, Cabaletta Bio Inc. From 11/10/25

Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient use All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who ...

PHILADELPHIA, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company w...

A look at the top 10 most actives in the United States EPWK Holdings Ltd. (EPWK) rose 29.2% to $0.0855 on volume of 1,411,810,058 shares Yueda Digital Holding (YDKG) rose 21.6% to $0.0563 on volume of 591,315,290 shares UTime Limited (WTO) rose 6.9% to $0.0463 on volume of 326,794,845 share...

A look at the top 10 most actives in the United States EPWK Holdings Ltd. (EPWK) rose 29.2% to $0.0855 on volume of 1,384,347,396 shares Yueda Digital Holding (YDKG) rose 21.6% to $0.0563 on volume of 580,113,283 shares AMTD Digital Inc. American Depositary Shares (every five of which repre...

– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses with no immunomodulators – – Myositis registrational trial b...

– Gavel brings highly relevant CAR T experience from Legend Biotech where he led the launch and commercialization of CARVYKTI® from 2018 until 2025 – PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company...

– Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory patients; all three patients remained off immunomodulators since infusion and are off or tapering steroids as of the data cut-off – &#x...

2025-10-07 06:20:31 ET Topline Summary and Update Read the full article on Seeking Alpha For further details see: Cabaletta Bio: Still Optimistic, With News Being Guided To Be Shared Soon

PHILADELPHIA, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company w...

Cabaletta Bio Inc. (CABA) is expected to report $-0.71 for Q2 2025